国新健康(000503) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥50,467,725.80, representing a 5.33% increase compared to ¥47,915,544.20 in the same period last year[3]. - The net profit attributable to shareholders was -¥45,576,538.97, a decrease of 12.86% from -¥40,381,786.35 year-over-year[3]. - The total operating revenue for the current period is CNY 50,467,725.80, an increase from CNY 47,915,544.20 in the previous period, representing a growth of approximately 5.5%[24]. - The net profit for the current period is -45,576,538.97, compared to -40,380,236.63 in the previous period, indicating a decline of approximately 12.5%[25]. - The total comprehensive income for the current period is -45,593,839.33, compared to -40,355,707.49 in the previous period, reflecting a decrease of about 13.5%[25]. - The basic and diluted earnings per share for the current period are both -0.0465, compared to -0.0412 in the previous period, indicating a worsening of approximately 8.0%[26]. Cash Flow and Assets - The net cash flow from operating activities improved by 34.66%, reaching -¥65,632,343.86 compared to -¥100,443,543.19 in the previous year[3]. - The company's cash and cash equivalents decreased to CNY 365,780,927.32 from CNY 451,840,676.26, a decline of about 19%[20]. - Cash and cash equivalents at the end of the period stand at 351,391,328.46, down from 816,969,617.12 at the end of the previous period, a decrease of about 56.9%[27]. - The operating cash flow for the current period is -65,632,343.86, an improvement from -100,443,543.19 in the previous period, showing a reduction in cash outflow by approximately 34.7%[26]. Assets and Liabilities - Total assets decreased by 3.35% to ¥1,992,785,005.50 from ¥2,061,938,679.96 at the end of the previous year[3]. - The total assets of the company as of March 31, 2025, are CNY 1,992,785,005.50, down from CNY 2,061,938,679.96 at the beginning of the period, reflecting a decrease of approximately 3.3%[22]. - The total liabilities decreased to CNY 632,772,661.63 from CNY 656,332,496.76, a reduction of about 3.6%[22]. - The company's total equity decreased to CNY 1,360,012,343.87 from CNY 1,405,606,183.20, indicating a decline of approximately 3.2%[22]. Investments and Expenses - Investment income surged by 212.51% to ¥4,320,158.46, attributed to the growth in net profits of joint ventures and interest income from large bank deposits[8]. - The total operating costs for the current period amount to CNY 101,542,262.28, up from CNY 90,887,714.68 in the previous period, indicating an increase of about 11.5%[24]. - Sales expenses increased by 35.28% to ¥14,923,130.53, reflecting higher investments in market development and sales personnel costs[8]. - The company incurred credit impairment losses of 3,398,061.31, which is significantly higher than 1,795,408.37 in the previous period, marking an increase of approximately 89.2%[25]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 70,199[10]. - The largest shareholder, China Oceanwide Holdings Group Co., Ltd., holds 24.02% of the shares, totaling 235,702,593 shares[10]. Corporate Governance - The company appointed Mr. Zhang Zhenhua as the vice president, effective immediately upon board approval[14]. - The company held a board meeting to elect candidates for the twelfth board of directors, including both independent and non-independent directors[15]. - The company has elected a new employee representative supervisor, Ms. Xia Kun, to join the newly formed 12th Supervisory Board[17]. - The company has proposed the nomination of two shareholder representative supervisors for the 12th Supervisory Board, pending approval[16]. - The company approved the repurchase and cancellation of 125,800 restricted stocks due to three individuals no longer meeting incentive conditions[13]. Organizational Changes - The company restructured its organization by dissolving the PBG Data R&D Department and establishing an AI Center to oversee AI infrastructure development[14]. - The company decided to continue using RMB 450 million of temporarily idle raised funds for cash management until January 28, 2026[13].